AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02582840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin, a blood glucose lowering drug. Oral dose
Study NCT02582840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet. Oral dose
Study NCT04973761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zirconium crowns
Description: Prefabricated pirmary anteroir teeth zirconium crowns
Study NCT04973761 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Strip composite crowns
Description: Strip composite crowns
Study NCT00293384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant 80mg once daily in the morning on days 2 and 3
Study NCT00293384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes
Study NCT00293384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.
Study NCT00293384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron hydrochloride
Description: Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
Study NCT03998124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer facilitator training
Description: Peer facilitation of a project-based activity without staff present
Study NCT03998124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Staff-led social activity
Study NCT01431807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: oral, for up to 52 weeks.
Study NCT04456998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB002 (seralutinib)
Description: Capsule containing GB002 (seralutinib)
Study NCT04456998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsule containing placebo
Study NCT04456998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic Dry Powder Inhaler
Description: Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery
Study NCT04456998 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Generic Dry Powder Inhaler
Description: Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery
Study NCT04067505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Dose: 15mg twice daily for three weeks, then 20mg once daily until six months after the operation. Application: oral
Study NCT04067505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dose: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until 6 months Duration: 6 months Frequency: once daily Application: oral
Study NCT04067505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin
Description: Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
Study NCT02579473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER-214
Description: SER-214 is a poly(2-ethyl-oxazoline) (POZ) polymer conjugate of the potent dopamine agonist rotigotine that is designed to provide continuous drug delivery following a single weekly injection
Study NCT03022149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doctormate® (200mmHg)
Description: Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
Study NCT03022149 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Doctormate® (60mmHg)
Description: Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
Study NCT02897739 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic resonance imaging
Description: Cardiac MRI and short MRI following USPIO infusion
Study NCT02897739 — intervention group
Intervention type: BIOLOGICAL
Intervention: Acute Inflammatory Activation study
Description: Blood sampling for exploration of type and level of inflammatory response
Study NCT02897739 — intervention group
Intervention type: RADIATION
Intervention: PET CT
Description: PET study for metabolic pathway study
Study NCT02897739 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychological assessment
Description: Assessment by a psychologist
Study NCT02837887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavior Therapy
Description: Undergo computerized cognitive behavior therapy
Study NCT05112497 — intervention group
Intervention type: OTHER
Intervention: No intervention procedure
Description: No intervention procedure
Study NCT03652298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memory structuring intervention + Vagal breathing
Description: The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).~In the MSI part, the patient will talk, and the therapist will note the different event parts and their real timing. Each time the patient says a feeling or sensation, the therapist will ask to verbally elaborate and provide the cause of these feelings and sensations. Then, the therapist will retell the story in a chronological manner, with verbal titles and causes for feelings and sensations. Finally, the patient will be asked to retell the story in this structured manner, after being explained how to do so.~vagal breathing (i.e., deep, paced breathing) is a way to increase HRV, and thus parasympathetic activation
Study NCT03652298 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: support and attention (usual care)
Description: support and attention (usual care)
Study NCT01823029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Study NCT01823029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enteral nutrition.
Study NCT01823029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of iron
Study NCT01594593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: group-based behavioral workshop to address cancer-related distress
Study NCT02398539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: 0.5% cream
Study NCT03529942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Extended-release 32 mg FX006 IA injection
Study NCT02426281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab- paclitaxel 125mg/m2 D1, 8 15 every 4 weeks.
Study NCT02426281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
Study NCT00145509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asenapine
Description: Asenapine 5 or 10 mg twice daily (BID) sublingually for 40 weeks
Study NCT00145509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fast-dissolving tablet; twice daily (BID) sublingually for 40 weeks
Study NCT02880982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Weekly oral softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3)
Study NCT02880982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly oral placebo softgel capsule
Study NCT02459756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beverage: Spray dried blackcurrant powder dissolved in water
Study NCT03261414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: A short preanesthetic hypnosis before induction of anesthesia
Study NCT03261414 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Standard care before induction of anesthesia
Study NCT04173507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study NCT04173507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study NCT04173507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Tosylate
Description: Given PO
Study NCT04091516 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low-fat plant-based diet
Description: Participants will follow a diet that consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. Except for light refreshments and tastings at the group sessions, no meals will be provided. Participants will handle their own food preparation and purchases, with guidance from the education team, with no restriction on energy intake.
Study NCT03963193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100mg/m\^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m\^2 ivggt on days 1, 2, 3, repeated every 21 days.
Study NCT03963193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 65 mg/m\^2 ivggt on days 1, 8, Cisplatin 30 mg/m\^2 ivggt on days 1, 8, repeated every 21 days.
Study NCT02218138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning 2 BREATHE
Description: Mindfulness-based group program
Study NCT02218138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colorado Blues
Description: Colorado Blues, Cognitive-behavioral depression prevention group
Study NCT04089579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord Tissue Mesenchymal Stromal Cells
Description: Human Umbilical Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC), isolated and expanded from umbilical cord tissue from allogeneic unrelated donors. One dose of 6x10e6 cells/kg administered intravenously.
Study NCT04089579 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: Placebo comparative infusion
Study NCT01823861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone-based intervention
Description: Automated voice message to support post-abortion contraception use every two weeks for total of three months. Direct follow up phone call by family planning counsellor depending on response to voice message.
Study NCT02670616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560 mg by mouth daily on day 1-21 per each cycle
Study NCT02670616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV, day 1
Study NCT00726219 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Femoral perineural catheter
Description: Comparison of 2 insertion distances (3 vs 7 cm) for a femoral perineural catheter in the context of major knee surgery.
Study NCT05023590 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablation of left atrium during mitral valve open chest intervention
Description: open chest mitral valve surgery (reconstruction or replacement) with additional ablation of left atrium by cryo or radio frequency method
Study NCT03854916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caminemos Juntas App
Description: A tailored mobile app that encourages Latinas and Hispanic women to walk together using location-based services.
Study NCT03854916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: World Walking App
Description: A mobile app that encourages users to walk.
Study NCT00140075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin with Cyclophosphamide, followed by a Taxane
Description: Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2~Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2
Study NCT00140075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin with a Taxane
Description: Epirubicin = 75 mg/m2 per cycle~Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2
Study NCT02863978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal signal acquisitions
Description: Cardiac and respiratory signals are collected from the clinical monitoring routinely gathered in hospital neonatal units.~Movement quantification and baby's sounds are extracted thanks to a dedicated system which will collect images and sound with microphones and cameras.
Study NCT03643003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Dosage: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon.
Study NCT02670616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 IV day 1
Study NCT02670616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 IV day 1
Study NCT02670616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4 mg/m2 IV on day 1
Study NCT02670616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 100mg per day on day 1-5
Study NCT03665740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol
Description: resveratrol is an OTC supplement
Study NCT03665740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: resveratrol is an OTC supplement
Study NCT02687451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone HCl
Description: Oral liquid and injection; dose to be determined by Independent Data Monitoring Committee (IDMC).
Study NCT02687451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator for the double-blinded, placebo-controlled multiple-dose phase.
Study NCT01236469 — intervention group
Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: A prospective follow-up Study Echocardiogram will be performed, as applicable, for those subjects who do not have echo data as of January 1, 2009.
Study NCT02813915 — intervention group
Intervention type: DEVICE
Intervention: NICOM
Description: Use of NICOM and PLR to obtain patient fluid status
Study NCT04369391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP363856 150 mg
Description: SEP363856 tablet 150 mg
Study NCT04369391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT04369391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin 400 mg
Description: moxifloxacin tablet 400 mg
Study NCT01780701 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Spectroscopy Imaging with rectal probe
Study NCT00613769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole + metronidazole
Description: trimethoprim-sulfamethoxazole (160mg/800mg)p.o.+ metronidazole (1200mg)p.o.
Study NCT00613769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefuroxime and metronidazole
Description: cefuromime 1500mg i.v. + metronidazole 1500mg i.v.
Study NCT04088812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo meat derivative + Placebo satiating compound
Description: Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound placebo diluted in water
Study NCT04088812 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo meat derivative + Placebo satiating compound
Description: Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound placebo diluted in water
Study NCT03643003 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Music therapy
Description: Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Dosage: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon.
Study NCT03643003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Music Verbal Interaction (Placebo)
Description: Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Dosage is the same as for music therapy: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon.
Study NCT03643003 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-Music Verbal Interaction (Placebo)
Description: Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Dosage is the same as for music therapy: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon.
Study NCT00937638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BOLD Diet
Description: Low-fat, high fruit and vegetable diet that includes lean beef (5oz/day)
Study NCT00937638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BOLD-X Diet
Description: Low-fat, moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet. Also high in fruits and vegetables
Study NCT00937638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified DASH Diet
Description: Low-fat, high fruit and vegetable diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors and metabolic syndrome
Study NCT00129233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: valsartan 80 to 160 mg daily
Study NCT00129233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5 to 10 mg daily.
Study NCT03212703 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Skills Training (MBST)
Description: 8-week mindfulness skills training sessions based on Mindfulness-Based Cognitive Therapy (MBCT) program by Zindel Segal, Mark Williams and John Teasdale
Study NCT03212703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist control (WLC)
Description: Observation surveys at baseline, mid-point and end-point of an 8-week period
Study NCT03794843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine Injection
Description: Nimodipine injection (trade name: Nimotop) manufactured by Bayer Pharma AG was used as the reference preparation
Study NCT03794843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine Injection (II)
Description: Nimodipine Injection (II) was supplied by Shenyang Dongxing Pharmaceutical Technology Co., Ltd
Study NCT02634138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revitive IX
Description: A foot plate Neuromuscular Electrical Stimulation Device
Study NCT01570023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Isometric Progressive Resistance Oropharyngeal Therapy
Description: Tongue press exercises consist of pressing the tongue against the sensors. Isometric exercises will focus on the anterior and posterior sensor. Subjects will be given a target pressure value for both the anterior and posterior sensor locations for which to aim when doing the exercises. Visual feedback on the display will signal the subject that they have attained their target pressure goal.
Study NCT03734848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Ultrasound Guided Pectoralis Nerve Block.
Description: Using a 20-gauge 5 cm needle. Injection bupivacaine 0.25% used as a local anesthetic. The block was performed in a supine position with the arm slightly abducted. The ultrasound probe was placed at the midclavicular level infero-laterally to locate the axillary artery and vein and then moved laterally toward the axilla until pectoralis major, pectoralis minor, and serratus anterior muscles were identified at the level of the fourth rib. The needle was inserted in-plane with respect to the ultrasound probe. A volume of 20 ml of local anesthetic solution was deposited in the fascial plane between pectoralis minor and serratus anterior muscle, followed by withdrawal of the needle to the fascial plane between the pectoralis major and pectoralis minor muscle, where a volume of 10 ml was deposited. The block was performed similarly on the opposite side. Care was taken not to cross the toxic dose of bupivacaine (3 mg/kg).